CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Research Site 9, New York, New York, United States
Research Site 1, Houston, Texas, United States
Research Site 7, Toronto, Ontario, Canada
Research Site 2, Duarte, California, United States
Research Site 1, Melbourne, Victoria, Australia
Research Site 7, Amsterdam, North Holland, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.